2016 American Transplant Congress
Sirolimus Regimen and Viral Serology as Risk Factors for Outcomes of Adult Kidney Transplants: 14-Year Cumulative Data in the United States.
Department of Medicine, Univ. of Florida, College of Medicine, Gainesville, FL.
BACKGROUND: The relative risks for patient mortality, graft loss and malignancy in the five years following kidney-only transplant (KT) based on sirolimus (SRL) regimen at…2016 American Transplant Congress
Donors with Isolated Anti-HBc (“HBcAb Only”) Antibodies: True Evidence for Past Infection or Laboratory Artifact? Toward a Simple Confirmatory Test for HBcAb.
Use of organs from donors positive for hepatitis B virus (HBV) markers may safely expand the donor pool. Recently the American Society of Transplantation expert…2016 American Transplant Congress
An Economical and Effective Vaccination Program in Patients Transplanted for Hepatitis B Virus Related Liver Diseases: A Prospective Study.
Aims: To prospectively investigate the efficacy and safety of procedural HBV vaccination in patients transplanted for HBV related liver diseases for prevention of hepatitis B…2016 American Transplant Congress
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.
Background: Hepatitis B virus (HBV) reactivation is a well-known complication of immunosuppressive therapy in resolved HBV (hepatitis B surface antigen [HBsAg] negative and hepatitis B…2016 American Transplant Congress
Long-Term Liver Function of Deceased Liver Transplantation Using Hepatitis B Surface Antigen Positive Grafts.
Background: Deceased donors with hepatitis B [HBs Ag(+)] were not recommended to recover the livers for liver transplantation. However, in endemic area of hepatitis B…2016 American Transplant Congress
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
A large percentage of patients with end stage renal disease are known to be Hepatitis B virus (HBV) positive. A 2015 consensus guideline on use…2016 American Transplant Congress
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
IntroductionThe purpose of this study was to evaluate the incidence of post-transplant hepatitis B (HBV) reactivation in patients who have previously cleared hepatitis B surface…2016 American Transplant Congress
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
Background Hepatitis B virus(HBV) infection is common among uremia patients in China. Many patients received kidney transplantation are occult HBV carriers with HBsAg(-) and HBcAb(+)…2016 American Transplant Congress
The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.
Aim: We evaluated the incidence, risk factors and clinical course of liver transplanted pediatric patients with de novo hepatitis B infection and the clinical course…2015 American Transplant Congress
Replacement of Lamivudine By Telbivudine to Improve Renal Function for Post-Transplant Hepatitis B Patients – A Randomized Clinical Trial
Background: Lamivudine is one of the anti-hepatitis B virus (HBV) agents to prevent HBV recurrence after transplantation because lamivudine is safe for long-term use. However,…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »